Deutsche Bank cuts Oxford Biomedica to Hold as revenue conversion slows
Investing.com -- Oxford BioMedica shares fell 1.3% to 486.5 pence on Tuesday as investors digested a more cautious analyst view of the cell-and-gene therapy company following its recent revenue guidance cut. The stock’s latest decline comes as the shares remain well below their 52-week high of 950 pence, while broker views remain broadly positive but price targets have not translated into a near-term catalyst for the stock.
Reported by 2 outlets — Investing.com · Stock Market. See all sources ↓
Investing.com -- Oxford BioMedica shares fell 1.3% to 486.5 pence on Tuesday as investors digested a more cautious analyst view of the cell-and-gene therapy company following its recent revenue guidance cut. The stock’s latest decline comes as the shares remain well below their 52-week high of 950 pence, while broker views remain broadly positive but price targets have not translated into a near-term catalyst for the stock. Investec, for example, previously rated Oxford BioMedica Buy with a 772-pence price target, according to its published rating history. The more immediate pressure follows Oxford BioMedica’s Aug.
Read the full report at Investing.com · Stock Market ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- Investing.com -- Oxford BioMedica shares fell 1.3% to 486.5 pence on Tuesday as investors digested a more cautious analyst view of the cell-and-gene therapy company following its recent revenue guidance cut. The stock’s latest decline comes as the shares remain well below their 52-week high of 950 pence, while broker views remain broadly positive but price targets have not translated into a near-term catalyst for the stock.
- How widely is it covered?
- 2 outlets, average source rating 6.0/10.
- When was it last updated?
- 5m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Why is Oxford BioMedica stock sliding today?
Sources1TypeCoverageInvesting.com · Stock Market